medigraphic.com

2021, Number 1

<< Back Next >>

Folia 2021; 15 (1)

Therapeutic options for the reactional states of leprosy

Darias DC, Torres CCA, Ramírez FM, González MS

Language: Spanish
References: 17
Page: 1-10
PDF size: 200.72 Kb.


ABSTRACT

Introduction: The reactional states of leprosy are episodes of sudden increase in clinical activity that occur during the evolution of the disease over time, as a consequence of losing the balance maintained between the mycobacterium and the patient's immune system. In this period, there are hypersensitivity responses that interrupt the chronic course of the disease, and acute inflammation manifests, which are the main cause of nerve lesions and disabilities in leprosy.
Objective: To update the information about the treatments indicated in the reactional states of leprosy.
Methods: A bibliographic review was carried out with the articles on the topic available in SciELO, the WHO, the PAHO, VHL-Cuba, PubMed Central, Medline and Medigraphic. The descriptors used were lepra [leprosy] and tratamiento [managment]. Seven books and ten articles were cited, 71 % of which were published within the last five years.
For the management of reactional states, analgesic, antiinflammatory and immunosuppressive drugs, among others, are available. The type of reactional state and its severity define the therapeutic scale to be used. In mild cases, analgesics and nonpharmacological measures such as rest will be used. Glucocorticoids are the mainstay in the initial management of severe forms of lepra reaction.
Conclusions: Correct management of leprosy and early identification of reactional states prevent neurological damage and disabilities produced by this entity. Corticosteroids continue to be the first line of treatment for leprosy reactions.


REFERENCES

  1. Bolognia JL, Schaffer JV, Cerroni L. Dermatología. 4 ed. USA: Elsevier; 2018. p. 1296-303.

  2. Arenas R. Dermatología: Atlas, diagnóstico y tratamiento. 7 ed. México: McGraw-Hill Interamericana; 2019. p. 425-38.

  3. Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell D, Wolff K. Fitzpatrick Dermatología en Medicina General. Tomo II. 8 ed. Buenos Aires: Editorial Panamericana; 2016. p. 2253-62.

  4. Organización Mundial de la Salud. Lepra/Enfermedad de Hansen: manejo de reacciones y prevención de discapacidades. EE.UU.: Orientación técnica; 2021. [acceso 08/10/2020]. Disponible en: https://apps.who.int/iris/handle/10665/340710

  5. Riveros R, Contreras R, Galeano G, Di Martino Ortíz B, Rodríguez M, et al. Reacciones leprosas simulando vasculitis cutáneas. Reporte de 3 casos y revisión de la literatura. Rev. Parag. Reumatol. 2019;5(1):33-8. DOI: https://doi.org/10.18004/rpr/2019.05.01.33-38

  6. Manzur J, Díaz Almeida JA, Cortés Hernández M. Dermatología. La Habana: Editorial Ciencias Médicas; 2002. p. 200-22

  7. Ferrándiz Foraster C. Dermatología clínica. 4 ed. Barcelona, España: Elsevier; 2014. p. 31-4.

  8. Bielsa Marsol I. Indicaciones de talidomida y sus derivados en dermatología. PIEL, Form Contin en Dermatología. 2013;8:606-13. DOI: https://dx.doi.org/10.1016/j.piel.2013.01.017

  9. Falabella R, Victoria Chaparro J, Barona Cabal MI. Fundamentos de Medicina Dermatología. 8 ed. Medellín, Colombia: CIB fondo editorial; 2017. p. 201-10.

  10. Chaves W, Castro C, Garzón K, Fontalvo MT, Viracacha G, Ruano C, et al. Eritema nudoso secundario a reacción tipo 2 como manifestación de lepra lepromatosa. Un reporte de caso. Repert Med y Cirugía. 2016;25(4):241-6. Disponible en: https://dx.doi.org/10.1016/j.reper.2016.11.002

  11. García Leyva Y, Brito Chávez M, González González K. Lepra lepromatosa y eritema nudoso leproso: evolución natural. Folia Dermatológica Cubana. 2020 [acceso 09/10/2020];14(1):1-9. Disponible en: http://revfcd.sld.cu/index.php/fdc/article/view/192

  12. Pulido Pérez A, Suárez Fernández R. Tratamiento de las leprorreacciones. PIEL, Form Contin en Dermatología. 2015;6:4-9. DOI: https://dx.doi.org/10.1016/j.piel.2015.04.015

  13. Salud Pública, Ministerio de salud. LEPRA. Normas técnicas para el control y tratamiento. La Habana, Cuba: Editorial Ciencias Médicas; 2008. p. 1-56.

  14. Hoyos-Gómez C, Cardona-Castro N. Reacciones leprosas. Rev CES Med. 2016;30(2):200-9. DOI: https://dx.doi.org/10.21615/cesmedicina.30.2.7

  15. Walker SL, Nicholls PG, Dhakal S, Hawksworth RA, Macdonald M. A Phase Two Randomised Controlled Double Blind Trial of High Dose Intravenous Methylprednisolone and Oral Prednisolone versus Intravenous Normal Saline and Oral Prednisolone in Individuals with Leprosy Type 1 Reactions and/ or Nerve Function Impairment. PLoS Negl Trop Dis. 2011;5(4):e1041. DOI: https://dx.doi.org/10.1371/journal.pntd.0001041

  16. Wagenaar I, Post E, Brandsma W, Bowers B, Alam K, Shetty V, et al. Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial. Plos Negl Trop Dis. 2017;11(10):e0005952. DOI: https://dx.doi.org/10.1371/journal.pntd.0005952

  17. Aldama A. Fenómeno de Lucio. Comunicación de 14 casos. Piel (Barc). 2017;33(2):81-5. DOI: https://doi.org/10.1016/j.piel.2017.09.012




2020     |     www.medigraphic.com